Alnylam Pharmaceuticals (ALNY) Surged on Strong Growth and Optimistic Revenue Outlook

2 days ago 2

Soumya Eswaran

Thu, November 13, 2025 astatine 8:07 AM CST 3 min read

ClearBridge Investments, an concern absorption company, released its “ClearBridge Mid Cap Strategy” third-quarter 2025 capitalist letter. A transcript of the missive tin beryllium downloaded here. In an situation of shifting monetary policy, stabilizing earnings, and improved sentiment, midcaps experienced maturation successful the 3rd quarter. The Federal Reserve’s determination to chopped rates helped tiny and mid-cap stocks successful the quarter. Value stocks outperformed their maturation counterparts with the Russell Midcap Value Index returning 6.2% compared to the Russell Midcap Growth’s 2.8% return. In this environment, the strategy outperformed its Russell Midcap Index during the 3rd quarter. Stock enactment successful the user staples and healthcare sectors drove outperformance of the strategy. In addition, delight cheque the fund’s apical 5 holdings to cognize its champion picks successful 2025.

In its third-quarter 2025 capitalist letter, ClearBridge Mid Cap Strategy highlighted stocks specified arsenic Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) discovers and commercializes therapeutics based connected ribonucleic acerb interference. The one-month instrumentality of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) was -3.73%, and its shares gained 75.54% of their worth implicit the past 52 weeks. On November 12, 2025, Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) banal closed astatine $452.74 per share, with a marketplace capitalization of $59.81 billion.

ClearBridge Mid Cap Strategy stated the pursuing regarding Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) successful its 3rd 4th 2025 capitalist letter:

"Health attraction was different cardinal operator of outperformance, anchored by spot successful biotechnology and the summation of caller opportunities successful beingness sciences tools. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) besides advanced, driven by accelerating uptake of its attraction for transthyretin cardiac amyloidosis (ATTR-CM) and a rise to full-year gross guidance, reinforcing assurance successful its commercialized execution and heavy RNA-based cause pipeline."

Is Alnylam Pharmaceuticals, Inc. (ALNY) the Best Growth Stock to Buy According to Billionaires?

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is not connected our database of 30 Most Popular Stocks Among Hedge Funds. As per our database, 58 hedge money portfolios held Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) astatine the extremity of the 2nd quarter, which was 59 successful the erstwhile quarter. In the 3rd 4th of 2025, the merchandise gross of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) grew 103% year-over-year to $851 million. While we admit the imaginable of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.